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Abstract
Background: The presence of diabetes mellitus increases the risk of several severe infections, but data on its effect
on treatment outcomes in patients with nosocomial pneumonia (NP) caused by methicillin-resistant Staphylococcus
aureus (MRSA) are limited.
Methods: We retrospectively analyzed data from a double-blind, randomized, multi-center, international clinical trial
of culture-confirmed MRSA NP that compared treatment with linezolid to vancomycin. Specifically, we evaluated
the clinical and microbiologic outcomes of patients with and without diabetes in the modified intent to treat
population at end-of-treatment (EOT) and end-of-study (EOS, 7–30 days post-EOT).
Results: Among 448 enrolled patients 183 (40.8 %) had diabetes mellitus, 87 (47.5 %) of whom received linezolid
and 96 (52.5 %) vancomycin. Baseline demographic and clinical characteristics were similar for the two treatment
groups. Clinical success rates at EOS were 57.6 % with linezolid and 39.3 % with vancomycin, while microbiological
success rates were 58.9 % with linezolid and 41.1 % with vancomycin. Among diabetic patients, rates of mortality
and study drug-related adverse effects were similar between the treatment groups. Overall day 28 mortality rates
were higher among diabetic patients compared to non-diabetic patients (23.5 vs 14.7 %, respectively: RD = 8.8 %,
95 % CI [1.4, 16.3]).
Conclusions: Among diabetic patients with MRSA NP, treatment with linezolid, compared to vancomycin, was
associated with higher clinical and microbiologic success rates, and comparable adverse event rates.
Trial registration: NCT00084266.
Keywords: Linezolid, Diabetes mellitus, MRSA, Vancomycin, Pneumonia, Mortality, Outcome, Staphylococcus,
Infection, Prognosis
Abbreviations: AE, Adverse events; ELF, Epithelial lining fluid; EOS, End-of-study; EOT, End-of-treatment;
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Background
Persons with diabetes mellitus, compared with non-
diabetic persons, have higher rates of impaired immunity
[1, 2], decreased lung function [3, 4], and an increased
risk for various types of infection, including pneumonia
[5, 6]. Methicillin-resistant Staphylococcus aureus
(MRSA) has emerged over the last decade as a common
etiologic agent of nosocomial pneumonia, especially in
intensive care units (ICUs). For example, the prevalence
of MRSA as a cause of nosocomial pneumonia (NP) in
intensive care units (ICU) has been reported as 37 % in
Germany, 54 % in the US and 78 % in Asia and Latin
America [5]. Patients with diabetes appear to be at in-
creased risk for acquiring S. aureus pneumonia [6–8],
and patients requiring renal dialysis are at risk for
hospital-acquired pneumonia, healthcare associated
pneumonia and ventilator associated pneumonia caused
by multi-drug resistant pathogens [8]. A recent study by
Haque and colleagues found that 28-day mortality rates
were higher among ICU patients with MRSA pneumonia
when they had comorbid diabetes [9].
Current guidelines for the management of adults with
hospital-acquired, ventilator-associated and healthcare-
associated pneumonia issued jointly by the American
Thoracic Society and the Infectious Diseases Society of
America (IDSA) recommend either linezolid or vanco-
mycin as appropriate antibiotic agents for the treatment
of MRSA nosocomial pneumonia (NP) [8]. The guide-
lines do not, however, address the potential for worse
outcomes of this infection in a patient with diabetes, nor
how the presence of this comorbidity might affect selec-
tion of antibiotic therapy. Presumably, this is based on a
lack of published data on these issues.
We hypothesized that the immune and lung dysfunc-
tion commonly associated with diabetes may lead to a
worse response to antibiotic treatment for MRSA
pneumonia among these patients compared with non-
diabetic patients. Further, because there has been a con-
sistent trend in published trials toward better outcomes
with treatment of MRSA pneumonia with linezolid than
with other antibiotic agents [10–12] we wished to inves-
tigate the potential effect of underlying diabetes on treat-
ment outcomes with linezolid versus vancomycin. To
evaluate our hypothesis we conducted a post-hoc, sub-
group analysis of data taken from a recent large, multi-
center, prospective, randomized controlled study to
examine the effect of diabetes mellitus on clinical and
microbiologic outcomes in patients treated with either
linezolid or vancomycin for culture-confirmed MRSA
NP [12].
Methods
We retrospectively analyzed data from a prospective,
multicenter, international study comparing linezolid
(600 mg twice a day) to vancomycin (15 mg/kg twice a
day, with dose adjustment as necessary based on trough
levels and creatinine clearance) administered for 7–14
days for the treatment of NP confirmed by culture to be
caused by MRSA. The previously published main study
provides details of the study design and overall results
[12]. The study was approved by an institutional review
board or ethics committee at each investigational site.
Investigators obtained written informed consent from
each patient or legally authorized representative. Briefly,
male and female patients ≥18 years old were enrolled if
they had NP (defined as at least two clinical signs and
symptoms consistent with pneumonia [i.e., new or wors-
ening cough or purulent sputum, auscultatory findings
of pneumonia, dyspnea, tachypnea, hypoxemia or new
respiratory failure requiring mechanical ventilation] ac-
quired after 48 h in an inpatient healthcare or chronic-
care facility, or after recent hospitalization [within
90 days] or undergoing chronic dialysis within 30 days),
and a respiratory specimen for culture. Potential patients
were not excluded based on their baseline blood glucose
levels; no baseline hemoglobin A1c levels were recorded.
Patients could receive up to two days of non-study anti-
biotic therapy prior to randomization or study entry.
A local, unblinded pharmacist prepared the study
medication, monitored and adjusted vancomycin doses
according to local protocols and measurements of
trough vancomycin levels and renal function. The inves-
tigators and patients were blinded throughout the study.
Pending culture results, all patients could initially re-
ceive an antibiotic with activity against aerobic gram-
negative bacterial pathogens, but not one with activity
against MRSA; mixed infections were treated with add-
itional agents for gram-negative antibiotic coverage. Pa-
tients were clinically assessed at baseline, on day 3 and
every 3 days during treatment. Respiratory cultures were
repeated 48–72 h after treatment initiation, at end of
treatment (EOT), and at end of study (EOS, defined as
7–30 days after EOT).
The current analysis included only the modified-
intent-to-treat (MITT) population, defined as patients
who received at least one dose of study drug and had
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culture-proven MRSA pneumonia. Since we used previ-
ously collected data without personal identifiers for this
secondary analysis we did not obtain a separate ethics
consent. We classified patients into those with, and
those without, diabetes mellitus, based on the data re-
corded by the investigator on the comorbidity case re-
port forms provided for each enrolled patient. Clinical
outcome was primarily assessed by the investigator
within 5 days of EOT and at EOS, with occasional over-
ride by the sponsor based on the criteria of Additional
file 1: Table S1. Any revisions in classification of out-
come were made before unblinding. Microbiologic re-
sponses were determined at EOT and EOS, based on the
results of repeat cultures obtained from the original in-
fection site. Additional file 1: Table S1 provides the defi-
nitions of clinical and microbiologic outcomes. We also
assessed all treatment-related adverse events (AE), ser-
ious adverse events (SAEs), AEs that led to study drug
discontinuation, and day 28 and day 60 (all-cause)
mortality.
Statistical analysis
To assess statistical differences in the distribution of
baseline characteristics between the two treatment
groups, we used one-way analysis of variance for con-
tinuous variables and Fisher’s exact test or the chi-
square test, as appropriate, for categorical variables.
Prior to analysis of clinical and microbiologic response
and mortality, a Breslow-Day test was conducted to
evaluate the homogeneity of treatment for the non-
randomized diabetes subgroups. We excluded patients
who were classified in the “unknown” (clinical) or “inde-
terminate” (microbiologic) categories from statistical
analysis of response. To assess the association of vari-
ables with clinical response and mortality among pa-
tients with diabetes and MRSA NP, we performed
multivariate logistic regression analyses. Prior to model
building we took into consideration covariate reduction
techniques: near zero variance, missingness and covari-
ate correlations, associations and clusters. We identified
variables for inclusion in the final multivariate logistic
regression model based on selection in at least 50 % of
1000 bootstrap samples, where the model for each boot-
strap was selected by backward elimination with an
alpha stay criterion of 0.05. Baseline variables in the
multivariate analysis included: type of antibiotic treat-
ment; age; weight; sex; race; presence of infiltrate on
chest x-ray; presence of pleural effusion; Acute Physi-
ology and Chronic Health Evaluation (APACHE) score
at baseline; presence of bacteremia; ICU admission at
baseline; pathogen type (cultures positive for MRSA
alone or in conjunction with other gram-positive, gram-
negative or anaerobic organism[s]); type of ward or ser-
vice on which the patient was hospitalized (surgical,
medical, vs trauma); admission from a long term care fa-
cility; presence of co-morbidities (e.g., neoplastic, renal/
urinary, pulmonary, hepatobiliary, vascular, gastrointes-
tinal); medications at baseline; a history of undergoing
renal dialysis; baseline blood glucose; smoking status
(current, ex-smoker or nonsmoker); pneumonia type
(ventilator-associated, hospital-associated or healthcare
associated); and, minimum inhibitory concentration
(MIC) of the organism against linezolid and vancomycin.
We used 2-sided tests for all statistical comparisons and
considered p-values <0.05 as statistically significant. For
statistical procedures we used SAS, version 9.2 (SAS In-
stitute, Cary, NC).
Results
Study population and patient demographics
Overall, 448 enrolled patients met the study entry cri-
teria, 183 of whom had diabetes and 265 were non-
diabetic. Among the patients with diabetes, 87 (47.5 %)
were randomized to receive linezolid and 96 (52.5 %) to
receive vancomycin. Among non-diabetic patients 137
(51.7 %) received linezolid and 128 (48.3 %) received
vancomycin. The majority of patients with diabetes were
insulin-treated at enrollment: 66.7 % among the
linezolid-treated and 77.1 % among the vancomycin-
treated patients.
Demographic and baseline characteristics were similar
between the linezolid and vancomycin treatment groups
(Table 1). Compared to the non-diabetic patients, the
diabetic patients had a significantly higher percent: older
than 50 years of age; heavier than 75 kg; with an APA-
CHE II score ≥20; or, with a cardiac, vascular, renal or
gastrointestinal comorbidity (Table 1). The diabetic and
non-diabetic groups were not statistically different in
their baseline microbiological results, vancomycin MICs,
clinical pulmonary infection scores, percent of patients
who were ventilated or had bacteremia, frequency of
pleural effusion (43.7 vs 45.7 %, p = 0.70) or bilateral
lung involvement on chest X-ray (72.1 vs. 66.4 % p =
0.17).
The baseline non-fasting blood glucose levels were
similar between the diabetic and non-diabetic linezolid
treated patients (mean ± SD 176.3 ± 116.7 mg/dL vs.
164.7 ± 152.7 mg/dL), and non-diabetic vancomycin
treated patients (167.8 ± 123.5 mg/dL for diabetic vs.
174.9 ± 158.9 mg/dL) (Table 1).
Treatment outcomes
The outcomes by diabetes subgroup are similar to those
overall observed in the primary study, particularly in
regards to EOS, EOT outcomes and mortality [12]. The
duration of antibiotic therapy provided was similar for
the two treatment arms and among the diabetic and
non-diabetic patients (Table 1). On treatment days 3, 6
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Table 1 Demographic and clinical characteristics of diabetic and non-diabetic patients treated with either linezolid or vancomycin
for MRSA-nosocomial pneumonia in the modified intent to treat (MITT) population
Diabetic Patients (N = 183) Non-diabetic Patients (N = 265)
Characteristic Linezolid N = 87 Vancomycin N = 96 Linezolid N = 137 Vancomycin N = 128
Age (y), mean (SD) *** 67.1 (13.0) 69.8 (12.8) 58.2 (19.8) 56.1 (19.3)
Male Sex, n (%) 57 (65.5) 55 (57.3) 94 (68.6) 88 (68.8)
Race, n (%)
White 59 (67.8) 60 (62.5) 97 (70.8) 92 (71.9)
Black 11 (12.6) 15 (15.6) 14 (10.2) 16 (12.5)
Asian 12 (13.8) 17 (17.7) 20 (14.6) 16 (12.5)
Other 5 (5.7) 4 (4.2) 6 (4.4) 4 (3.1)
Treatment duration (days), mean (SD) 9.7 (4.1) 9.1 (4.9) 10.1 (3.8) 10.0 (4.1)
Baseline blood glucose (mg/dl), na/mean (SD) 83/176.3 (116.7) 91/167.8 (123.5) 129/164.7 (152.7) 121/174.9 (158.9)
Bacteremia, n (%)
Yes 6 (6.9) 10 (10.4) 9 (6.6) 14 (10.9)
No 78 (89.7) 85 (88.5) 116 (84.7) 110 (85.9)
Unknown 3 (3.4) 1 (1.0) 12 (8.8) 4 (3.1)
Insulin at Baseline n (%) 58 (66.7) 74 (77.1) N/A N/A
Ventilated at baseline, n (%) 58 (66.7) 70 (72.9) 95 (69.3) 93 (72.7)
APACHE Score, n (%) ***
< 20 50 (57.5) 52 (54.2) 91 (66.4) 87 (68.0)
≥ 20 36 (41.4) 42 (43.8) 43 (31.4) 39 (30.5)
Unknown 1 (1.1) 2 (2.1) 3 (2.2) 2 (1.6)
CPIS score, na/mean (SD) Baseline 56/9.6 (2.2) 63/9.5 (2.1) 89/9.5 (2.1) 91/9.2 (2.4)
Chest x-ray, n (%)b
Unilateral 20 (23.0) 29 (30.2) 39 (28.5) 50 (39.1)
Bilateral 65 (74.7) 67 (69.8) 98 (71.5) 78 (60.9)
Pleural effusion, n (%) 42 (48.3) 38 (39.6) 63 (46.0) 58 (45.3)
Weight (kg), na/mean (SD) *** 87/85.6 (26.8) 96/79.2 (22.4) 137/73.2 (18.0) 127/76.2 (20.4)
Comorbidities, n (%)
Cardiac *** 58 (66.7) 69 (71.9) 73 (53.3) 68 (53.1)
Hepatobiliary 13 (14.9) 10 (10.4) 21 (15.3) 21 (16.4)
Gastrointestinal *** 57 (65.5) 56 (58.3) 71 (51.8) 63 (49.2)
Neoplastic 8 (9.2) 13 (13.5) 12 (8.8) 12 (9.4)
Renal/Urinary *** 40 (46.0) 53 (55.2) 43 (31.4) 41 (32.0)
Pulmonary 65 (74.7) 67 (69.8) 87 (63.5) 87 (68.0)
Vascular *** 38 (43.7) 37 (38.5) 38 (27.7) 41 (32.0)
Baseline pathogens, n (%)
MRSA only 53 (60.9) 62 (64.6) 66 (48.2) 66 (51.6)
MRSA + other Gr (+) 6 (6.9) 9 (9.4) 16 (11.7) 9 (7.0)
MRSA + other Gr (-) 19 (21.8) 18 (18.8) 41 (29.9) 38 (29.7)
MRSA+ other Gr (+) and Gr (-) 5 (5.7) 3 (3.1) 8 (5.8) 10 (7.8)
MRSA + anaerobes 0 1 (1.0) 0 1 (0.8)
MRSA + fungal 4 (4.6) 3 (3.1) 6 (4.4) 4 (3.1)
Baseline Vancomycin MICs, n (%)
≤ 0.5 7 (8.0) 2 (2.1) 10 (7.3) 12 (9.4)
1 63 (72.4) 75 (78.1) 105 (76.6) 93 (72.7)
2 7 (8.0) 7 (7.3) 6 (4.4) 11 (8.6)
4 0 1 (1.0) 0 1 (0.8)
unknown 10 (11.5) 11 (11.5) 16 (11.7) 11 (8.6)
Abbreviations: CPIS clinical pulmonary infection score, MRSA methicillin-resistant S. aureus, SD standard deviation
aDenotes the number of patients with available data when different than the group total
bAmong diabetic patients treated with linezolid, 1 had a normal chest x-ray and one had unknown chest x-ray findings
*P < 0.05 for linezolid vs vancomycin treated diabetic patients; ** P < 0.05 for linezolid vs vancomycin treated non-diabetic patients; *** P < 0.05 for diabetic pa-
tients vs. non-diabetic patients
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and 9 the vancomycin trough levels (in 03BCg/ml me-
dian [(min, max]) were 13.3 (4.4, 36.1), 15.0 (6.4, 41.4)
and 18.0 (4.9, 26.2) among diabetic patients and 11.7
(2.8, 50.8), 14.7 (2.7, 45.0) and 13.7 (2.0, 46.9) among
non-diabetic patients. The duration of ventilation and
antibiotic treatment (data not shown), EOT and EOS
overall clinical outcomes (Fig. 1) and microbiologic out-
comes (Fig. 2) were similar between diabetic and non-
diabetic groups.
Among the diabetic patients, clinical and microbiologic
success rates at EOT and EOS were higher among linezo-
lid treated patients as compared to those treated with
vancomycin (Figs. 1 and 2). At EOT clinical success was
noted in 82.4 % of diabetic patients treated with linezolid
versus 64.8 % of diabetic patients treated with vancomycin
(risk difference [RD], 95 % confidence intervals [CI]:
17.6 %, [4.5, 30.7]). Similarly, at EOT microbiologic suc-
cess was noted for 83.8 % of diabetic patients treated with
linezolid vs. 57.0 % of diabetic patients treated with vanco-
mycin (RD, 95 % CI: 26.8 % [13.7, 39.9]). At the EOS visit,
clinical success was found in 57.6 % of the diabetic pa-
tients treated with linezolid and 39.3 % of those treated
with vancomycin [RD, 95 % CI: 18.2 % (2.6, 33.9)]; EOS
microbiologic success was noted for 58.9 % of diabetic pa-
tients treated with linezolid and 41.1 % of those treated
with vancomycin (RD, 95 % CI: 17.8 % [2.6, 33.0]).
Among the non-diabetic patients, clinical and microbi-
ologic success rates at EOT and EOS were similar be-
tween treatment groups, except for clinical response at
EOT (Figs. 1 and 2). At EOT, clinical success was noted
in 76.7 % of non-diabetic patients treated with linezolid
versus 59.2 % of non-diabetic patients treated with
vancomycin (risk difference [RD], 95 % confidence inter-
vals [CI]: 17.5 %, [6.3, 28.8]).
A multivariate regression analysis was conducted to
evaluate the association between baseline factors and
clinical response at EOT and EOS among patients with
diabetes (Table 2). The final multivariate model for clin-
ical response at EOT had the following predictors: com-
bined MIC; vasopressor use; smoking status; study drug,
bacteremia; and, pneumonia type. The final multivariate
model for clinical response at EOS had the following
predictors: race; and, vasopressor use. Diabetic patients
treated with linezolid were 2.8 times more likely to have
clinical success at EOT than those treated with vanco-
mycin (p = 0.02). Second, diabetic patients without
bacteremia accompanying their NP were 5 times more
likely to have clinical success at EOT compared to those
with bacteremia (p = 0.009). At EOS diabetic patients
who were not on vasopressors at baseline were 3.3 times
as likely to have clinical success compared to those who
were, and Asian diabetic patients were almost 5 times
Fig. 1 Clinical outcomes in patients with MRSA-NP treated with either linezolid or vancomycin by diabetes mellitus status in the MITT population.
Risk Difference (RD) & 95 % Confidence Interval (CI) are presented for treatment group difference and for overall diabetes group differences in
percent success. Percentages do not include patients with unknown outcomes
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more likely to have clinical success at EOS compared
with white diabetic patients.
All-cause mortality within 28 days after randomization
was higher among diabetic patients compared to non-
diabetic patients (23.5 vs 14.7 %, RD = 8.8 %, 95 % CI
[1.4, 16.3]), but was similar for linezolid and vancomycin
treated diabetic patients (20.7 % for linezolid versus
26.0 % for vancomycin) and non-diabetic patients
(17.5 % for linezolid versus 11.7 % for vancomycin). Re-
sults for all-cause mortality within 60 days after
randomization were non-significantly higher among dia-
betic patients compared to non-diabetic patients [29.5 vs
23.0 %, RD = 6.5 %, 95 % CI (-1.8, 14.8)]. Adverse events
resulting in death that were reported for more diabetic
patients compared to non-diabetic patients were cardio-
vascular and cerebrovascular events, respiratory arrest
and septic shock. Among diabetic patients, pneumonia,
as an adverse event resulting in death, was reported for
more linezolid-treated patients compared to
vancomycin-treated patients. Adverse events resulting in
death reported for more vancomycin-treated diabetic pa-
tients than linezolid-treated diabetic patients were
multi-organ failure, respiratory failure, sepsis and septic
shock.
A multivariate regression analysis was conducted to
evaluate the association between baseline factors and
day 28 mortality among patients with diabetes (Table 2).
The final multivariate model for mortality had the fol-
lowing predictors: age; history of chronic renal dialysis;
race; hospitalization service type; bacteremia; and,
pleural effusion. There was a six-fold increased risk of
death within 28 days of randomization among diabetic
patients who were receiving chronic renal dialysis and a
significantly increased risk of death with increasing age
(a 1.4-fold increase for every 10 year increase in age).
Furthermore, diabetic patients with pleural effusion were
half as likely to die compared to diabetic patients with-
out pleural effusion. Asian diabetic patients were 10
times less likely to die compared to white diabetic
patients.
Safety
Rates of treatment-related adverse events, as well as
study drug discontinuations due to adverse events, were
similar for diabetic and non-diabetic patients in the
MITT population. The percentages of treatment-related
adverse events, and study drug discontinuations were
also similar between the two drug treatment groups
(Table 3).
Discussion
Patients with diabetes mellitus have been reported to be at
high risk for colonization and several types of infection with
MRSA, especially pneumonia and soft tissue infections
[13–17]. Furthermore, some previous studies suggest that
diabetic patients with complicated MRSA skin and soft tis-
sue infections respond less well to treatment compared to
non-diabetic patients [18–20]. In a diabetic mouse model,
treatment with either systemic linezolid or daptomycin had
a more rapid therapeutic effect compared with vancomycin,
but after day 1, all three antibiotics had similar efficacy
against MRSA wound infection [21]. A study looking at the
effect of the addition of a macrolide antibiotic to initial
therapy with a third generation-beta lactam among patients
Fig. 2 Microbiologic outcomes in patients with MRSA-NP treated with either linezolid or vancomycin by diabetes mellitus status in the MITT
population. Risk Difference (RD) & 95 % Confidence Interval (CI) are presented for treatment group difference in percent success. Percentages do
not include patients with unknown outcomes
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with community acquired pneumonia did not show a dif-
ference between diabetic and non-diabetic subgroups [22].
We are not aware of any studies similar to ours on the
role of co-morbid diabetes mellitus in patients with noso-
comial pneumonia. A systematic review and meta-analysis
published in 2013 found 9 studies comparing treatment of
hospital-acquired pneumonia (of any cause) with linezolid
versus vancomycin [23]. The results suggested that the
two drugs had similar efficacy and safety profiles, includ-
ing for infections caused by MRSA, but there was no
breakdown in results based on the presence of diabetes.
Thus, we conducted an analysis of data obtained from a
recent large, randomized, prospective, multi-national clin-
ical trial of culture confirmed MRSA NP. Our results
show that treatment of diabetic patients with linezolid re-
sulted in higher clinical and microbiologic success rates at
EOT and EOS compared to treatment with vancomycin.
In contrast, there were no significant differences for clin-
ical and microbiologic success rates between the treat-
ment arms among non-diabetic patients.
It would be reasonable to expect the random blood
glucose levels to be higher in the diabetic patients, but
Table 2 Multivariate logistic regression modelling in patients with diabetes
Variable Adjusted OR 95 % CI P value
Clinical Success (mITT Population)
End of Treatment
Vasopressors at Baseline (Yes vs No) 0.4 (0.2, 1.1) 0.073
Treatment (LZD vs. VAN) 2.8 (1.2, 6.8) 0.022
Bacteremia (Yes vs No) 0.2 (0.1, 0.7) 0.009
Combined MIC (vs. 0.5)
1 1.5 (0.2, 9.1) 0.673
2 or 4 0.4 (0.1, 3.2) 0.384
Pneumonia Type
HCAP vs. HAP 2.9 (0.6, 13.7) 0.176
VAP vs. HAP 0.6 (0.2, 1.5) 0.239
HCAP vs. VAP 5.2 (1.3, 21.6) 0.023
Smoking Status
Current vs. Non-Smoker 0.9 (0.3, 2.4) 0.774
Ex vs. Non-Smoker 2.3 (0.8, 6.1) 0.105
End of Study
Vasopressors at Baseline 0.3 (0.1, 0.8) 0.019
Race (vs White)
Asian 4.9 (1.7, 13.6) 0.002
Black 1.7 (0.7, 4.3) 0.281
Other 1.1 (0.2, 5.5) 0.885
Day 28 Mortality (mITT population)
Age (10 years) 1.4 (1.1, 1.9) 0.014
Chronic Dialysis Care (Yes vs No) 5.9 (1.8, 19.6) 0.004
Race (vs. White)
Asian 0.1 (0.0, 0.5) 0.004
Black 1.0 (0.4, 2.6) 0.987
Other 0.8 (0.1, 3.9) 0.735
Subject Type (vs. Medical)
Surgical 1.0 (0.4, 2.2) 0.921
Trauma 1.3 (0.4, 5.1) 0.665
Bacteremia (Yes vs. No) 2.2 (0.8, 6.0) 0.115
Pleural Effusion (Yes vs. No) 0.5 (0.2, 1.0) 0.040
CI confidence interval, mITT modified intent-to-treat OR odds ratio
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they were not in this study. This may be because the dia-
betic patients had received prior treatment for glycemic
control. In addition, the elevated blood glucose levels in
the non-diabetic patients could at least be partly attrib-
utable to the stress of acute illness. It is also possible
that some “non-diabetics” may be undiagnosed diabetics
(or have pre-diabetes).
The concentration of vancomycin in lung epithelial lining
fluid (ELF) is dependent upon blood vancomycin levels and
alveolar capillary membrane protein permeability [18, 24],
and is an important determinant of vancomycin antibacter-
ial activity against MRSA in the lung [25]. Linezolid has
been shown to have better ELF penetration than vanco-
mycin in animal models of MRSA NP [26]. A meta-analysis
of pulmonary function found that patients with diabetes
have higher rates of restrictive lung disease [4], and post-
mortem histologic examination of lung tissue from patients
with diabetes mellitus showed thickening of alveolar epithe-
lial and pulmonary capillary basal laminae [27]. In our re-
view of the literature we found no data on vancomycin ELF
concentrations in patients with diabetes mellitus. In this
double-blind clinical trial vancomycin trough levels were
monitored and adjusted by local pharmacists and were
similar between patients with and without diabetes mellitus;
however, due to underlying lung pathology it may be that
vancomycin penetration into pulmonary sites of infection is
reduced, lessening the likelihood of cure of infection.
In our study the 28 day mortality rate for patients who
had MRSA NP was higher among diabetic than non-
diabetic patients, regardless of the treatment arm. A
study by Falguera and colleagues reported an increased
mortality among diabetic patients with community-
acquired pneumonia that they attributed to underlying
conditions, such as neoplastic disease, congestive heart
failure, cerebrovascular disease, chronic renal disease,
chronic obstructive pulmonary disease, chronic liver dis-
ease and HIV infection [28]. Patients with diabetes have
also been shown to be at higher risk than non-diabetics
for MRSA bacteremia [13, 29, 30]. In our study, the fre-
quencies of multi-lobar pneumonia, pleural effusion and
MRSA bacteremia were similar in the diabetic and non-
diabetic patients with MRSA-NP. Perhaps not surpris-
ingly, increasing age and undergoing chronic renal dialy-
sis were associated with an increased mortality risk
among diabetic patients. We also observed that the oc-
currence of cardiovascular and cerebrovascular events,
as well as respiratory failure and septic shock, were
events resulting in death more frequently reported for
diabetic patients compared to non-diabetic patients. Of
note, diabetic patients who were Asian, or who had
pleural effusion at baseline were less likely to die from
their MRSA-NP. Although recent studies suggest that
body fat and lean mass content and fat distribution are
different in Asians, and these differences may potentially
lead to heterogeneity in the clinical presentation of age-
related chronic diseases between ethnicities [31], we
cannot assess the effect of race on treatment outcome
from this study.
Our study has several limitations. First, it was based
on a retrospective review of prospectively obtained data
and was not planned a priori. Second, it is a subgroup
analysis with a relatively small sample size in some
Table 3 Adverse events among diabetic and non-diabetic patients in the modified-intent-to-treat population
Diabetic Patients (N = 183) Non-diabetic Patients (N = 265)
Adverse event (AE) n (%) Linezolid N = 87 Vancomycin N = 96 Linezolid N = 137 Vancomycin N = 128
Patients with a treatment- related AE 22 (25.3) 26 (27.1) 46 (33.6) 43 (33.6)
Patients with a serious AE 33 (37.9) 45 (46.9) 56 (40.9) 36 (28.1)
Patients with study drug discontinuation due to AE 3 (3.4) 8 (8.3) 9 (6.6) 9 (7.0)
Patients with specific AEs:
Diarrhea 12 (13.8) 14 (14.6) 28 (20.4) 20 (15.6)
Rasha 6 (6.9) 8 (8.3) 16 (11.7) 9 (7.0)
Nausea 7 (8.0) 7 (7.3) 10 (7.3) 11 (8.6)
Vomiting 3 (3.4) 4 (4.2) 8 (5.8) 8 (6.3)
Thrombocytopeniad 17 (20.7) 13 (14.3) 18 (13.5) 15 (12.3)
Kidney impairmentb 3 (3.4) 13 (13.5) 5 (3.6) 9 (7.0)
IV site complicationsc 3 (3.4) 5 (5.2) 6 (4.4) 6 (4.7)
aRash includes the following AE preferred terms: Genital rash, Rash, Rash erythematous, Rash generalized, Rash macular, Rash maculo-papular, Rash popular and
Rash pustular
bKidney Impairment includes the following AE preferred terms: Renal failure, Renal failure acute, Renal failure chronic and Renal impairment
c IV Site Complications include the following AE preferred terms: Catheter site erythema, Catheter site haematoma, Catheter site haemorrhage, Catheter site
infection, Catheter site pain, Infusion site cellulitis, Infusion site erythema, Infusion site extravasation, Infusion site infection, Infusion site phlebitis and Infusion
site thrombosis
dThrombocytopenia was defined as a platelet count of <150,000 μL, if platelet count was normal at baseline, or a 50 % drop if platelet count was not normal
at baseline
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groups, therefore making it difficult to identify small but
potentially clinically important differences. Third, we
conducted an interaction test that showed no significant
differences in treatment responses between the diabetic
and non-diabetic patients. Fourth, the diagnosis of dia-
betes in enrolled patients was based on information pro-
vided by the investigators. We had no data on the
patient’s baseline hemoglobin A1C levels, which may
have helped elucidate the relationship of prior glycemic
control among patients with diabetes in the outcome of
these infections. Additionally, diabetes mellitus is a
disorder with a broad spectrum of severity. Identifying
the type of diabetes (1 versus 2) and measurements of
glycemic control (serum glucose or glycosylated
hemoglobin) have limited ability to define the severity of
the disease. As such, results should be interpreted with
caution and considered as hypothesis-generating, rather
than confirmatory. Given that treatment responses may
differ between diabetic and non-diabetic patients, inves-
tigators in future clinical trials may wish to consider
whether diabetic, pre-diabetic and non-diabetic groups
should be stratified prior to randomization.
Conclusions
A key finding in our study was that among diabetic pa-
tients with MRSA NP the cure rate was significantly
higher among those treated with linezolid compared
with those treated with vancomycin. Regardless of treat-
ment arm, the 28-day mortality rate was higher among
patients with diabetes than among non-diabetics, but
were similar for linezolid and vancomycin treated dia-
betic patients. Increased mortality among the patients
with diabetes mellitus was associated with increasing age
and having received chronic renal dialysis. If our findings
are replicated by other investigators, clinicians might
consider treating diabetic patients with MRSA-NP with
linezolid.
Additional file
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